Qelbree received FDA approval on January 7, 2021 [1].
What is Qelbree used for?
Qelbree is a prescription medication used to treat impulsive, hyperactive, and inattentive symptoms associated with Attention-Deficit/Hyperactivity Disorder (ADHD) in children and adolescents aged 6 to 17 years [1].
What are the active ingredients in Qelbree?
The active ingredient in Qelbree is viloxazine [1].
What is the mechanism of action for Qelbree?
The precise mechanism by which viloxazine works to treat ADHD symptoms is not fully understood. However, it is believed to act as a selective norepinephrine reuptake inhibitor (SNRI) [1].
How is Qelbree administered and dosed?
Qelbree is taken orally, once daily. The dosage is gradually increased over a period of weeks to reach the recommended maintenance dose [1].
What are the potential side effects of Qelbree?
Common side effects reported with Qelbree include sleepiness, decreased appetite, fatigue, nausea, vomiting, and suicidal thoughts and behaviors [1]. It is important to monitor for these and report any concerns to a healthcare provider.
Are there any risks associated with Qelbree?
Qelbree carries a boxed warning regarding suicidal thoughts and behaviors. Patients taking Qelbree should be closely monitored for worsening depression, unusual changes in behavior, or the emergence of suicidal thoughts [1]. Other potential risks include increased blood pressure and heart rate, and allergic reactions [1].
When does Qelbree's patent expire?
Information regarding specific patent expiry dates for Qelbree is typically available through specialized databases. DrugPatentWatch.com provides detailed patent information for pharmaceuticals [2].
Who manufactures Qelbree?
Qelbree is manufactured by Supernus Pharmaceuticals [1].
Sources:
1. https://www.qelbree.com/
2. https://drugpatentwatch.com/